Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt N/A
JNJ's Cash to Debt is ranked higher than
81% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. JNJ: N/A )
Ranked among companies with meaningful Cash to Debt only.
JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 1.62 Max: 6.28
Current: N/A
0.46
6.28
Equity to Asset 0.54
JNJ's Equity to Asset is ranked lower than
62% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. JNJ: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.56 Max: 0.67
Current: 0.54
0.51
0.67
Interest Coverage 148.61
JNJ's Interest Coverage is ranked higher than
51% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 123.58 vs. JNJ: 148.61 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 37.54 Max: 230.91
Current: 148.61
28.29
230.91
F-Score: 4
Z-Score: 5.01
M-Score: -2.79
WACC vs ROIC
8.18%
31.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 26.09
JNJ's Operating margin (%) is ranked higher than
89% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. JNJ: 26.09 )
Ranked among companies with meaningful Operating margin (%) only.
JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 24.96 Max: 28.2
Current: 26.09
22.36
28.2
Net-margin (%) 21.99
JNJ's Net-margin (%) is ranked higher than
88% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. JNJ: 21.99 )
Ranked among companies with meaningful Net-margin (%) only.
JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 19.87 Max: 21.96
Current: 21.99
14.87
21.96
ROE (%) 25.90
JNJ's ROE (%) is ranked higher than
89% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. JNJ: 25.90 )
Ranked among companies with meaningful ROE (%) only.
JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 25.24 Max: 30.17
Current: 25.9
17.02
30.17
ROA (%) 14.07
JNJ's ROA (%) is ranked higher than
86% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. JNJ: 14.07 )
Ranked among companies with meaningful ROA (%) only.
JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 13.58 Max: 17.94
Current: 14.07
8.93
17.94
ROC (Joel Greenblatt) (%) 96.93
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. JNJ: 96.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 103.58
Current: 96.93
65.66
103.58
Revenue Growth (3Y)(%) 3.50
JNJ's Revenue Growth (3Y)(%) is ranked lower than
59% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. JNJ: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.30 Max: 14.8
Current: 3.5
1.4
14.8
EBITDA Growth (3Y)(%) 14.60
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. JNJ: 14.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 10.95 Max: 16.5
Current: 14.6
-6.6
16.5
EPS Growth (3Y)(%) 17.80
JNJ's EPS Growth (3Y)(%) is ranked higher than
68% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. JNJ: 17.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 10.50 Max: 20.2
Current: 17.8
-8.6
20.2
» JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

JNJ Guru Trades in Q1 2015

Ray Dalio 268,093 sh (+316.99%)
John Buckingham 61,885 sh (+27.51%)
Manning & Napier Advisors, Inc 2,802,122 sh (+18.71%)
Jeremy Grantham 13,268,899 sh (+13.43%)
Mairs and Power 2,118,878 sh (+9.76%)
Joel Greenblatt 833,196 sh (+5.40%)
John Rogers 657,074 sh (+3.95%)
RS Investment Management 8,578 sh (+3.25%)
James Barrow 15,676,362 sh (+1.19%)
First Eagle Investment 1,627,823 sh (+0.67%)
Ken Fisher 10,456,816 sh (+0.31%)
Yacktman Fund 3,900,000 sh (unchged)
Tom Gayner 574,200 sh (unchged)
T Rowe Price Equity Income Fund 4,633,000 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Richard Snow 3,270 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Perry 312,610 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Ruane Cunniff 75,937 sh (-0.01%)
Richard Pzena 1,174,016 sh (-0.84%)
Mario Gabelli 333,155 sh (-1.12%)
Jeff Auxier 91,676 sh (-1.77%)
Donald Yacktman 8,432,672 sh (-2.08%)
Tweedy Browne 4,055,962 sh (-2.09%)
Murray Stahl 30,674 sh (-2.26%)
PRIMECAP Management 11,858,877 sh (-2.34%)
Yacktman Focused Fund 3,000,000 sh (-3.23%)
Pioneer Investments 2,622,793 sh (-3.66%)
Sarah Ketterer 855,044 sh (-8.12%)
Dodge & Cox 39,985 sh (-9.61%)
Michael Price 25,000 sh (-28.57%)
Paul Tudor Jones 56,058 sh (-39.50%)
Jim Simons 867,200 sh (-62.89%)
John Hussman 1,325 sh (-98.81%)
» More
Q2 2015

JNJ Guru Trades in Q2 2015

David Dreman 6,648 sh (New)
Sarah Ketterer 1,207,926 sh (+41.27%)
John Rogers 782,026 sh (+19.02%)
Manning & Napier Advisors, Inc 3,292,140 sh (+17.49%)
Paul Tudor Jones 63,433 sh (+13.16%)
John Buckingham 63,439 sh (+2.51%)
Ruane Cunniff 77,357 sh (+1.87%)
Mairs and Power 2,158,264 sh (+1.86%)
Ken Fisher 10,641,756 sh (+1.77%)
Jeff Auxier 91,926 sh (+0.27%)
Richard Pzena 1,174,169 sh (+0.01%)
Richard Snow 3,270 sh (unchged)
Robert Olstein 71,000 sh (unchged)
T Rowe Price Equity Income Fund 4,633,000 sh (unchged)
John Hussman 1,325 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Michael Price 25,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
RS Investment Management 8,578 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
James Barrow 15,632,757 sh (-0.28%)
First Eagle Investment 1,610,098 sh (-1.09%)
Murray Stahl 29,841 sh (-2.72%)
Jeremy Grantham 12,907,199 sh (-2.73%)
Tweedy Browne 3,918,801 sh (-3.38%)
PRIMECAP Management 11,370,350 sh (-4.12%)
Dodge & Cox 38,235 sh (-4.38%)
Mario Gabelli 315,150 sh (-5.40%)
Richard Perry 292,729 sh (-6.36%)
Yacktman Fund 3,500,000 sh (-10.26%)
Donald Yacktman 7,441,948 sh (-11.75%)
Yacktman Focused Fund 2,500,000 sh (-16.67%)
Pioneer Investments 2,068,266 sh (-21.14%)
Ray Dalio 194,993 sh (-27.27%)
» More
Q3 2015

JNJ Guru Trades in Q3 2015

Chuck Royce 9,000 sh (New)
Charles Brandes 118,509 sh (New)
John Burbank 32,624 sh (New)
Louis Moore Bacon 63,428 sh (New)
Jim Simons 392,000 sh (New)
Manning & Napier Advisors, Inc 4,406,762 sh (+33.86%)
Sarah Ketterer 1,593,359 sh (+31.91%)
RS Investment Management 10,457 sh (+21.90%)
Jeff Auxier 110,226 sh (+19.91%)
Pioneer Investments 2,381,190 sh (+15.13%)
John Rogers 884,154 sh (+13.06%)
Yacktman Focused Fund 2,600,000 sh (+4.00%)
Yacktman Fund 3,600,000 sh (+2.86%)
John Buckingham 64,896 sh (+2.30%)
Donald Yacktman 7,560,334 sh (+1.59%)
Tom Gayner 582,200 sh (+1.39%)
Murray Stahl 30,179 sh (+1.13%)
Mairs and Power 2,181,707 sh (+1.09%)
Mario Gabelli 317,847 sh (+0.86%)
T Rowe Price Equity Income Fund 4,672,800 sh (+0.86%)
Ken Fisher 10,689,483 sh (+0.45%)
Warren Buffett 327,100 sh (unchged)
Richard Perry 292,729 sh (unchged)
Richard Pzena 1,174,169 sh (unchged)
Michael Price 25,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Richard Snow 3,270 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
John Hussman 1,325 sh (unchged)
David Dreman Sold Out
Ruane Cunniff 76,400 sh (-1.24%)
James Barrow 15,399,839 sh (-1.49%)
First Eagle Investment 1,585,928 sh (-1.50%)
Tweedy Browne 3,855,936 sh (-1.60%)
Dodge & Cox 36,935 sh (-3.40%)
PRIMECAP Management 10,575,867 sh (-6.99%)
Jeremy Grantham 11,529,743 sh (-10.67%)
Ray Dalio 167,593 sh (-14.05%)
Paul Tudor Jones 47,878 sh (-24.52%)
» More
Q4 2015

JNJ Guru Trades in Q4 2015

John Hussman 26,325 sh (+1886.79%)
Jim Simons 655,300 sh (+67.17%)
Pioneer Investments 3,824,174 sh (+60.60%)
Charles Brandes 151,094 sh (+27.50%)
Mario Gabelli 332,287 sh (+4.54%)
John Buckingham 65,746 sh (+1.31%)
Ken Fisher 10,815,964 sh (+1.18%)
Richard Pzena 1,174,524 sh (+0.03%)
T Rowe Price Equity Income Fund 4,672,800 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Richard Snow 3,260 sh (-0.31%)
James Barrow 15,342,046 sh (-0.38%)
Donald Yacktman 7,316,129 sh (-3.23%)
Yacktman Focused Fund 2,500,000 sh (-3.85%)
Tweedy Browne 3,693,349 sh (-4.22%)
Jeff Auxier 105,426 sh (-4.35%)
Ray Dalio 109,693 sh (-34.55%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Johnson & Johnson

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Bill Frels Comments on Johnson & Johnson - Oct 20, 2014

Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

John Rogers' Ariel Fund Comments on Johnson & Johnson - Feb 28, 2014

Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled...

After its slide in the current century, Johnson & Johnson took the opportunity to reinvigorate itself. Alex Gorsky, who became CEO in 2012, led a major transformation; he charged his new operations head, Sandra Peterson, with structural improvements across the company. On the pharmaceutical side, it refocused its Research & Development (R&D) on blockbuster segments such as anti-coagulants and oncology. In its medical technology division, the company boldly exited the underperforming drug-eluding stent business and deployed foreign cash through the acquisition of high-margin specialty implant maker Synthes, a Swiss company. Johnson & Johnson even bolstered its consumer brands such as Neutrogena and Band-Aid, which offer lower margins but steady cash flows. More importantly, it has gotten past the embarrassing 2010 recalls of the children's versions of Tylenol, Motrin, Zyrtec and Benadryl, and all four are now back on the shelves. We always look forward, even when analyzing a 127-year old company, and at this point see a lean, mean heavyweight ready to compete.

From John Rogers (Trades, Portfolio)' Ariel International Fund & Ariel Global Fund fourth quarter 2013 commentary by Rupal J. Bhansali.

Check out latest stock trades

Top Ranked Articles about Johnson & Johnson

5 Guru Picks in Volatile Biotech Industry Johnson & Johnson and Merck each have the backing of more than 25 gurus
Biotech and pharmaceutical stocks made some of the biggest headlines this year, as 2015 saw massive waves of M&A activity, including the Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) merger, the second-largest deal of all time valued at $160 billion. Other companies found themselves in the spotlight for less than desirable reasons, such as Valeant Pharmaceuticals (NYSE:VRX), whose stock has tanked in the past several months. Read more...
Mairs and Power Buys American Express, Pfizer in 3rd Quarter Firm increases stake in American Express by 87%
Mairs and Power (Trades, Portfolio) Inc. is an investment firm whose strength and success has resulted from applying a conservative growth investment approach consistently for over 70 years. The following are its most notable buys during the third quarter. Read more...
Charles Brandes Buys Stakes in Emerson Electric, Johnson & Johnson Guru adds more than 3 million shares to stake in Leucadia National
Charles Brandes (Trades, Portfolio), chairman of Brandes Investment Partners, the firm he founded in 1974, is an adherent of value investing, applying its principles to the portfolios that are managed by the firm as well as his own. The strategy has been successful. Last year, when many investors struggled in a challenging environment, Brandes’ U.S. Value Equity Fund produced positive returns exceeding 13%. Read more...
Charles Brandes Comments on Johnson & Johnson Guru stock highlight
Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s. Read more...
The Best Way to Reinvest Your Dividends for Retirement There are two primary strategies that can be implemented to reinvest dividends
The Best Way to Reinvest Your Dividends for Retirement Read more...
Joel Greenblatt Sells Johnson & Johnson, Flowserve A look at the Magic Formula inventor's largest trades
Joel Greenblatt (Trades, Portfolio) is the founder and managing partner of Gotham Asset Management LLC, which offers four diversified long/short equity mutual funds. Read more...
The Two Keys to the Magic Formula for Long-Term Investment Success Estimating future earnings growth is the second major key to successful long-term investing
Investing in anything comes with a degree of uncertainty because all investing returns happen in the future. And even though the future is unpredictable, the future is what everyone who invests is investing for. These realities present important challenges that every investor must face and deal with in order to succeed. Read more...
Tweedy Browne Reduces 33 Stakes in Portfolio
For nearly a century, Tweedy Browne (Trades, Portfolio) has been advising investors and managing funds in accord with the principles of Benjamin Graham. Last year, Tweedy Browne (Trades, Portfolio)’s strategy produced better than a 4% return. In the two preceding years, the returns were in double digits – 22.68% in 2013 and 15.45% in 2012. Read more...
Weekly Insider Sells Highlight: JNJ, TRV, AAL, STJ
According to GuruFocus Insider Data, the largest insider sells during the past week were: Johnson & Johnson, Travelers Companies Inc, American Airlines Group Inc, and St Jude Medical Inc. Read more...
Google Set To Bring In A Difference In The World Of Surgery
The technology giant, Google (NASDAQ:GOOG), has always striven to develop the best-in-kind products for the market and is often branded as the tech expert in the industry for its expertise in search optimization and its roaring popularity in the technology space. However, Google’s advent in the healthcare segment has been a sporadic one and does not find much of a mention by the analysts who follow the healthcare segment in the U.S. But currently the Google research team of biologists and chemists are in the top news section as Google is hoping to bring in advanced technology that could help surgeons to perform surgeries in a better way. Let’s get into the facts which have come into the limelight in the past few days with respect to Google’s strategic move to cater to the healthcare domain. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 19.41
JNJ's P/E(ttm) is ranked higher than
71% of the 753 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.84 vs. JNJ: 19.41 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24.45
Current: 19.41
10.5
24.45
Forward P/E 14.62
JNJ's Forward P/E is ranked higher than
56% of the 417 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.22 vs. JNJ: 14.62 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 19.41
JNJ's PE(NRI) is ranked higher than
70% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.10 vs. JNJ: 19.41 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.68 Max: 24.44
Current: 19.41
10.5
24.44
P/B 3.93
JNJ's P/B is ranked lower than
70% of the 935 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. JNJ: 3.93 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.72 Max: 6.13
Current: 3.93
2.68
6.13
P/S 4.06
JNJ's P/S is ranked lower than
76% of the 936 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. JNJ: 4.06 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.86  Med: 4.28 Max: 5.83
Current: 4.06
2.86
5.83
PFCF 19.15
JNJ's PFCF is ranked higher than
72% of the 450 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.49 vs. JNJ: 19.15 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.29  Med: 16.51 Max: 24.69
Current: 19.15
10.29
24.69
POCF 15.41
JNJ's POCF is ranked higher than
71% of the 611 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.10 vs. JNJ: 15.41 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 9  Med: 13.18 Max: 18.86
Current: 15.41
9
18.86
EV-to-EBIT 18.17
JNJ's EV-to-EBIT is ranked higher than
58% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.36 vs. JNJ: 18.17 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.8  Med: 15.40 Max: 23.9
Current: 18.17
9.8
23.9
EV-to-EBITDA 15.31
JNJ's EV-to-EBITDA is ranked higher than
56% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.09 vs. JNJ: 15.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.5  Med: 13.30 Max: 18.7
Current: 15.31
8.5
18.7
PEG 5.49
JNJ's PEG is ranked lower than
74% of the 276 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. JNJ: 5.49 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.18  Med: 1.65 Max: 26.05
Current: 5.49
1.18
26.05
Shiller P/E 21.54
JNJ's Shiller P/E is ranked higher than
78% of the 165 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.30 vs. JNJ: 21.54 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.47  Med: 20.81 Max: 29.83
Current: 21.54
15.47
29.83
Current Ratio 2.51
JNJ's Current Ratio is ranked higher than
55% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. JNJ: 2.51 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.04 Max: 2.69
Current: 2.51
1.2
2.69
Quick Ratio 2.19
JNJ's Quick Ratio is ranked higher than
61% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. JNJ: 2.19 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.68 Max: 2.37
Current: 2.19
0.94
2.37
Days Inventory 116.36
JNJ's Days Inventory is ranked higher than
51% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. JNJ: 116.36 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 103.67 Max: 128.87
Current: 116.36
100.19
128.87
Days Sales Outstanding 59.20
JNJ's Days Sales Outstanding is ranked higher than
64% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. JNJ: 59.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.65  Med: 57.41 Max: 61.4
Current: 59.2
50.65
61.4
Days Payable 100.47
JNJ's Days Payable is ranked higher than
68% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. JNJ: 100.47 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.03 Max: 147.94
Current: 100.47
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.89
JNJ's Dividend Yield is ranked higher than
79% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. JNJ: 2.89 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 1.64  Med: 2.83 Max: 3.84
Current: 2.89
1.64
3.84
Dividend Payout 0.56
JNJ's Dividend Payout is ranked higher than
69% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. JNJ: 0.56 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.40 Max: 13.89
Current: 0.56
0.29
13.89
Dividend Growth (3y) 7.00
JNJ's Dividend Growth (3y) is ranked higher than
52% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. JNJ: 7.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13.20 Max: 17.1
Current: 7
7
17.1
Forward Dividend Yield 2.95
JNJ's Forward Dividend Yield is ranked higher than
77% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.95 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.11
JNJ's Yield on cost (5-Year) is ranked higher than
81% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.86 vs. JNJ: 4.11 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.33  Med: 4.03 Max: 5.46
Current: 4.11
2.33
5.46
3-Year Average Share Buyback Ratio -1.10
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. JNJ: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.9  Med: 0.40 Max: 2
Current: -1.1
-4.9
2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 158.91
JNJ's Price/Net Current Asset Value is ranked lower than
97% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.54 vs. JNJ: 158.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
JNJ' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 13.8  Med: 65.64 Max: 3248.67
Current: 158.91
13.8
3248.67
Price/Tangible Book 11.58
JNJ's Price/Tangible Book is ranked lower than
85% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. JNJ: 11.58 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.23  Med: 10.38 Max: 18.92
Current: 11.58
6.23
18.92
Price/Projected FCF 1.51
JNJ's Price/Projected FCF is ranked higher than
73% of the 498 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. JNJ: 1.51 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.84  Med: 1.39 Max: 3.6
Current: 1.51
0.84
3.6
Price/DCF (Earnings Based) 1.84
JNJ's Price/DCF (Earnings Based) is ranked lower than
51% of the 122 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. JNJ: 1.84 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.28
JNJ's Price/Median PS Value is ranked lower than
56% of the 851 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. JNJ: 1.28 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 1.14 Max: 1.88
Current: 1.28
0.74
1.88
Price/Peter Lynch Fair Value 3.74
JNJ's Price/Peter Lynch Fair Value is ranked lower than
69% of the 238 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.77 vs. JNJ: 3.74 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.22  Med: 1.75 Max: 4.32
Current: 3.74
1.22
4.32
Price/Graham Number 3.16
JNJ's Price/Graham Number is ranked lower than
65% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. JNJ: 3.16 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 3.16 Max: 5.87
Current: 3.16
1.97
5.87
Earnings Yield (Greenblatt) (%) 5.60
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. JNJ: 5.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.2  Med: 6.50 Max: 10.2
Current: 5.6
4.2
10.2
Forward Rate of Return (Yacktman) (%) 10.02
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.77 vs. JNJ: 10.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 14.70 Max: 18.4
Current: 10.02
1.8
18.4

More Statistics

Revenue(Mil) $70074
EPS $ 5.23
Beta0.89
Short Percentage of Float1.06%
52-Week Range $81.79 - 105.49
Shares Outstanding(Mil)2766.94

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 71,624 75,416 78,068
EPS($) 6.53 6.96 7.39
EPS without NRI($) 6.53 6.96 7.39

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, PFE, RHHBY, NVS, ABT » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. The brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. The brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO for the treatment of hepatitis C; INTELENCE and PREZISTA, treatments for HIV/AIDS; CONCERTA extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA/XEPLION, for the treatment of schizophrenia in adults; RISPERDAL CONSTA, for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE, a treatment for multiple myeloma; ZYTIGA, a treatment for metastatic castration-resistant prostate cancer; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT, to stimulate red blood cell production; and XARELTO, an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may cause to pulmonary embolism (PE) in patients undergoing hip or knee replace
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
Gilead, Johnson & Johnson or Roche? Feb 11 2016 
Consider This Market with Negligible Volatility and Consistently Rising Values Feb 05 2016 
Valeant's Share Price Continues to Decline Feb 05 2016 
Johnson & Johnson: Dividend Aristocrats Part 50 Jan 27 2016 
Three Stock Picks for 2016 Jan 15 2016 
Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
Why Dividend Growth Investing Should Be Your New Year’s Resolution Jan 03 2016 
Dividend Aristocrats Part 39: Kimberly-Clark Dec 30 2015 
5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
Analyzing Amgen's Dividend Hike Dec 20 2015 

More From Other Websites
How global MNCs convinced Indians to use sanitary napkins Feb 12 2016
Cramer: Hail to Those Who Choose Wisely Feb 11 2016
PepsiCo CEO Says She’s Never Seen Global Economy This Bumpy Feb 11 2016
[$$] J&J May See $4 Cash-Flow Cut From Remicade Copy Feb 11 2016
Johnson & Johnson (JNJ) Stock Closed Down, Pfizer Developing Biosimilar Feb 10 2016
Why Pfizer (PFE) Stock Is Rising Today Feb 10 2016
Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
The Generic Drug Battle Feb 10 2016
U.S. Futures Tick Higher as Janet Yellen Worries Over Economy Feb 10 2016
Johnson & Johnson Gets Extrapolated Feb 10 2016
Early movers: TWX, DIS, DB, SPLS, CNX, P & more Feb 10 2016
Johnson & Johnson’s Imbruvica Sees Increased Sales in 4Q15 Feb 10 2016
JNJ’s Pharmaceutical Segment Contributes 45.3% of Revenue in 4Q15 Feb 10 2016
Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
Harvard-based weight loss startup combines tech, human coach Feb 09 2016
Pfizer, Reynolds Among Recession Stock Plays — GE, GM For Recovery Feb 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK